98 related articles for article (PubMed ID: 14748435)
1. Adjuvant cytokine treatment of minimal residual disease after surgical therapy in mice carrying HPV16-associated tumours: cytolytic activity of spleen cells from tumour regressors.
Indrová M; Mikysková R; Jandlová T; Vonka V; Bubeník J; Bieblová J
Folia Biol (Praha); 2003; 49(6):217-22. PubMed ID: 14748435
[TBL] [Abstract][Full Text] [Related]
2. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF.
Mikysková R; Indrová M; Símová J; Jandlová T; Bieblová J; Jinoch P; Bubeník J; Vonka V
Int J Oncol; 2004 Jan; 24(1):161-7. PubMed ID: 14654953
[TBL] [Abstract][Full Text] [Related]
3. Interleukin 2 gene therapy of surgical minimal residual tumour disease: characterization of cytolytic effector cells from tumour progressors and regressors.
Hájková R; Indrová M; Jandlová T; Bubeník J; Reinis M
Folia Biol (Praha); 1999; 45(6):227-31. PubMed ID: 10732718
[TBL] [Abstract][Full Text] [Related]
4. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
[TBL] [Abstract][Full Text] [Related]
5. Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy.
Mikysková R; Bubeník J; Vonka V; Smahel M; Indrova M; Bieblová J; Símová J; Jandlová T
Int J Oncol; 2005 Feb; 26(2):521-7. PubMed ID: 15645139
[TBL] [Abstract][Full Text] [Related]
6. Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin.
Indrová M; Bubeník J; Mikysková R; Vonka V; Smahel M; Zák R; Símová J; Bieblová J; Mendoza L; Jandlová T
Int J Oncol; 2002 Mar; 20(3):643-6. PubMed ID: 11836582
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours.
Indrová M; Bieblová J; Jandlová T; Vonka V; Pajtasz-Piasecka E; Reinis M
Int J Oncol; 2006 Jan; 28(1):253-9. PubMed ID: 16328003
[TBL] [Abstract][Full Text] [Related]
8. Local IFN-gamma therapy of HPV16-associated tumours.
Mikysková R; Bieblová J; Símová J; Indrová M; Jandlová T; Vonka V; Smahel M; Bubeník J; Mendoza L
Folia Biol (Praha); 2003; 49(1):26-32. PubMed ID: 12630665
[TBL] [Abstract][Full Text] [Related]
9. HPV16-associated tumours: therapy of surgical minimal residual disease with dendritic cell-based vaccines.
Reinis M; Indrová M; Mendoza L; Mikysková R; Bieblová J; Bubeník J; Símová J
Int J Oncol; 2004 Oct; 25(4):1165-70. PubMed ID: 15375569
[TBL] [Abstract][Full Text] [Related]
10. MHC class I+ and class I- HPV16-associated tumours expressing the E7 oncoprotein do not cross-react in immunization/challenge experiments.
Símová J; Mikysková R; Vonka V; Bieblová J; Bubeník J; Jandlová T
Folia Biol (Praha); 2003; 49(6):230-4. PubMed ID: 14748438
[TBL] [Abstract][Full Text] [Related]
11. Depletion of T(reg) cells inhibits minimal residual disease after surgery of HPV16-associated tumours.
Símová J; Bubeník J; Bieblová J; Rosalia RA; Fric J; Reinis M
Int J Oncol; 2006 Dec; 29(6):1567-71. PubMed ID: 17088998
[TBL] [Abstract][Full Text] [Related]
12. Dissimilar anti-tumour reactions induced by tumour cells engineered with the interleukin-2 or interleukin-15 gene in nude mice.
Di Carlo E; Meazza R; Basso S; Rosso O; Comes A; Gaggero A; Musiani P; Santi L; Ferrini S
J Pathol; 2000 Jun; 191(2):193-201. PubMed ID: 10861581
[TBL] [Abstract][Full Text] [Related]
13. CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours.
Reinis M; Símová J; Indrová M; Bieblová J; Bubeník J
Int J Oncol; 2007 May; 30(5):1247-51. PubMed ID: 17390028
[TBL] [Abstract][Full Text] [Related]
14. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
15. Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16.
Bubeník J; Símová J; Hájková R; Sobota V; Jandlová T; Smahel M; Sobotková E; Vonka V
Int J Oncol; 1999 Mar; 14(3):593-7. PubMed ID: 10024696
[TBL] [Abstract][Full Text] [Related]
16. HPV 16-associated tumours: IL-12 can repair the absence of cytotoxic and proliferative responses of tumour infiltrating cells after chemotherapy.
Indrová M; Bieblová J; Rossowska J; Kuropka P; Pajtasz-Piasecka E; Bubeník J; Reinis M
Int J Oncol; 2009 Jan; 34(1):173-9. PubMed ID: 19082488
[TBL] [Abstract][Full Text] [Related]
17. Live cell vaccines expressing B7.1, monocyte chemoattractant protein 1 and granulocyte-macrophage colony stimulation factor derived from mouse HPV16-transformed cells.
Lakatosová-Andelová M; Jinoch P; Dusková M; Marinov I; Vonka V
Int J Oncol; 2008 Jan; 32(1):265-71. PubMed ID: 18097567
[TBL] [Abstract][Full Text] [Related]
18. Combination of intratumoral injections of vaccinia virus MVA expressing GM-CSF and immunization with DNA vaccine prolongs the survival of mice bearing HPV16 induced tumors with downregulated expression of MHC class I molecules.
Nemeckova S; Smahel M; Hainz P; Mackova J; Zurkova K; Gabriel P; Indrova M; Kutinova L
Neoplasma; 2007; 54(4):326-33. PubMed ID: 17822323
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy and immunotherapy of tumours induced by gene-modified HPV16-transformed cells.
Sobotková E; Dusková M; Smahel M; Holán V; Janousková O; Vonka V
Oncol Rep; 2004 Oct; 12(4):877-83. PubMed ID: 15375516
[TBL] [Abstract][Full Text] [Related]
20. Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model.
Welters MJ; Filippov DV; van den Eeden SJ; Franken KL; Nouta J; Valentijn AR; van der Marel GA; Overkleeft HS; Lipford G; Offringa R; Melief CJ; van Boom JH; van der Burg SH; Drijfhout JW
Vaccine; 2004 Dec; 23(3):305-11. PubMed ID: 15530672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
